Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy

  • Authors:
    • Nobutaka Nagai
    • Xiurong Tian
    • Keiji Mukai
    • Eiji Hirata
    • Tomoyo Kusuda
    • Yuko Shiroyama
    • Kazushi Shigemasa
    • Koso Ohama
  • View Affiliations

  • Published online on: November 1, 2003     https://doi.org/10.3892/ijmm.12.5.709
  • Pages: 709-714
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aims of this study were to examine the overexpression of COX-2 protein and its relationship to apoptosis in cervical carcinoma patients treated with neoadjuvant chemo-therapy (NAC), and to assess the potential role of COX-2 as a predictor of the response to NAC in a series of patients with cervical carcinoma. For immunohistochemical analysis, cervical cancer tissue samples were collected before NAC and 3 weeks after NAC using transcatheter arterial infusion of cisplatin from 40 patients who underwent surgery for advanced cervical carcinoma in stages IB, IIA and IIB and from 5 normal cervical tissues between 1991 and 2000 at the Department of Obstetrics and Gynecology, under informed consent. Patients were randomly assigned to receive one or two arterial infusions of cisplatin. COX-2 protein expression was detected by immunohistochemical staining and was classified as no expression for tumors with negative or <10%, while ≥10% positive staining was defined as overexpression. Detection of apoptosis was done by the TUNEL method. The percentage of cells with DNA fragmentation (apoptotic index, AI) was calculated before NAC and 3 weeks after NAC. The AI ratio (AI after NAC/AI before NAC) was also calculated. COX-2 expression was not detected in the normal cervix. Overexpression of COX-2 protein was detected in 18 out of 40 (45.0%) cervical cancers. A higher incidence of COX-2 protein overexpression was observed in patients with adenocarcinoma than in those with squamous cell carcinoma (p=0.1797, Fisher's exact text). The average AI value before and after NAC was 8.85 versus 11.82 respectively. In COX-2 protein-negative patients with squamous cell carcinoma, the AI ratio was 0.96±0.46 following one arterial infusion of cisplatin and 3.19±2.72 following two infusions of cisplatin. There was a significant positive correlation between apoptosis and the number of infusions of cisplatin (p=0.0098, Mann-Whitney, U-test). Our findings suggest that COX-2 protein expression could be used as a predictor of chemoresistance and that assessment of the COX-2 status could be useful to identify cervical cancer patients who may benefit from NAC.

Related Articles

Journal Cover

November 2003
Volume 12 Issue 5

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nagai N, Tian X, Mukai K, Hirata E, Kusuda T, Shiroyama Y, Shigemasa K and Ohama K: Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy. Int J Mol Med 12: 709-714, 2003
APA
Nagai, N., Tian, X., Mukai, K., Hirata, E., Kusuda, T., Shiroyama, Y. ... Ohama, K. (2003). Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy. International Journal of Molecular Medicine, 12, 709-714. https://doi.org/10.3892/ijmm.12.5.709
MLA
Nagai, N., Tian, X., Mukai, K., Hirata, E., Kusuda, T., Shiroyama, Y., Shigemasa, K., Ohama, K."Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy". International Journal of Molecular Medicine 12.5 (2003): 709-714.
Chicago
Nagai, N., Tian, X., Mukai, K., Hirata, E., Kusuda, T., Shiroyama, Y., Shigemasa, K., Ohama, K."Overexpression of cyclooxygenase-2 protein and its relationship to apoptosis in cervical carcinoma treated with neoadjuvant chemotherapy". International Journal of Molecular Medicine 12, no. 5 (2003): 709-714. https://doi.org/10.3892/ijmm.12.5.709